List view / Grid view
GABAA receptors represent a large and complicated family of ion channels that consist of at least 16 subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ) that have been shown to be vital for the normal functioning of the brain. These inhibitory ligand-gated channels have been shown to beimportant in sedation,…
Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell...
Drug discovery is a lengthy process that proceeds through several stages. High-throughput screening (HTS) utilising whole-cell-based screening assays plays a fundamental role as a starting point for identifying novel compounds in the drug discovery process.
New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center...
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
This whitepaper outlines how advances in real-time live-cell monitoring and analysis methods are addressing these changing needs.
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
26 April 2018 | By Charles River Laboratories
This webinar highlights cell based assays for Parkinson’s disease that include endpoints such as a-synuclein aggregation and mitophagy readouts.
Scientists have developed a breakthrough CRISPR gene-editing tool, that could allow researchers to quickly and precisely engineer multiple changes to the genetic code...
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
